CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011
Cash Flows from Operating Activities:
Net income	$ 26,239	$ 49,080
Non cash items:
Depreciation and amortization	46,741	37,256
Stock compensation expense	7,931	6,727
Loss on sales of property, plant and equipment	472	280
Unrealized loss from hedging activities	617	1,365
Contingent consideration income	0	(1,580)
Reversal of interest expense on contingent consideration	0	(574)
Change in operating assets and liabilities:
Increase in accounts receivable, net	(32,165)	(1,461)
Increase in inventories	(12,732)	(23,047)
(Increase)/decrease in prepaid income taxes	(1,673)	14,949
Increase in other assets and other long-term liabilities	(4,489)	(874)
Tax benefit of exercise of stock options	3,905	1,410
Increase/(decrease) in accounts payable and accrued expenses	22,686	(2,188)
Net cash provided by operating activities	57,532	81,343
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(49,685)	(36,959)
Proceeds from sale of property, plant and equipment	1,290	517
Acquisition of Whole Blood Business	(535,144)	0
Investment in Hemerus	(1,000)	0
Net cash used in investing activities	(584,539)	(36,442)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(658)	(882)
Net increase in short-term loans	4,557	1,529
Term Loan borrowings	475,000	0
Debt issuance costs	(5,461)	0
Proceeds from employee stock purchase plan	4,142	3,722
Proceeds from exercise of stock options	28,342	9,076
Excess tax benefit on exercise of stock options	3,158	839
Share repurchases	(18,042)	(49,998)
Net cash provided by (used in) financing activities	491,038	(35,714)
Effect of exchange rates on cash and cash equivalents	289	(522)
Net (Decrease)/Increase in Cash and Cash Equivalents	(35,680)	8,665
Cash and Cash Equivalents at Beginning of Year	228,861	196,707
Cash and Cash Equivalents at End of Period	193,181	205,372
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placements of Haemonetics equipment	19,606	10,912
Supplemental Disclosures of Cash Flow Information:
Interest paid	4,020	322
Income taxes paid	$ 8,900	$ 6,098